StockData

Verrica Pharmaceuticals vs Zentalis Pharmaceuticals

VRCA and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VRCA and ZNTL compare

Zentalis Pharmaceuticals is the larger company, worth 2.1 times as much as Verrica Pharmaceuticals ($115M against $55.0M).

Zentalis Pharmaceuticals scores higher on the StockData Score (6 against 4 for Verrica Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVRCAZNTL
Size and price
Market cap$55.0M$115M
Share price$3.20$1.60
Change, 1 year−17.3%21.2%
Change, 5 years−96.9%−97.9%
Beta (5Y)5.055.70
Employees76106
StockData Score
Total score46 (better)
Valuation score01 (better)
Growth score2 (better)0
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/S1.8×–
P/B12.8×0.8× (better)
FCF yield–−112%
Growth
Revenue growth (TTM)106%–
Profitability
Operating margin−93.6%–
Net margin−103%–
Return on equity–−66.7%
Financial health
Debt / equity–0.00
Interest coverage−7.6×–
Current ratio1.454.82 (better)
Altman Z-score−13.90−8.84 (better)
Piotroski F-score4 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions27.1%66.1%
Held by insiders–58.0%
Insider net buying, 12 months$211K$12.8M (better)
Short interest, % of float–16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.